NCT04345913 2026-03-19
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
National Cancer Institute (NCI)
BioNTech SE
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Sichuan Baili Pharmaceutical Co., Ltd.